# Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct06702995/  
OnCo record `nct06702995` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XNW5004, Enzalutamide in prostate cancer, run by Evopoint Biosciences Inc., now recruiting.

## Summary

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT06702995 by Evopoint Biosciences Inc., with 307 participants planned, started 2023-04-19 and due to reach its primary completion in 2026-05-13. Interventions recorded: XNW5004, enzalutamide. Conditions listed: Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06702995
- Phase: 1/2
- Setting: A Phase Ib/II Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Failed Prior Novel Hormone Therapy
- Sponsor: Evopoint Biosciences Inc.
- Enrolled: 307

## Sources

- ClinicalTrials.gov NCT06702995: https://clinicaltrials.gov/study/NCT06702995

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [XNW5004](https://onco.cc/drugs/xnw5004/)
- companies: [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06702995.json